Literature DB >> 16436747

Tissue penetration of telavancin after intravenous administration in healthy subjects.

Heather K Sun1, Kenneth Duchin, Charles H Nightingale, Jeng-Pyng Shaw, Julie Seroogy, David P Nicolau.   

Abstract

The pharmacokinetic disposition of telavancin administered 7.5 mg/kg of body weight every 24 h was determined in plasma and skin blister fluid. The mean penetration of telavancin into blister fluid was 40%. This study reveals that adequate concentrations are achieved in both plasma and blister fluid for pathogens frequently implicated in skin and soft tissue infections.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436747      PMCID： PMC1366897          DOI： 10.1128/AAC.50.2.788-790.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.

Authors:  Dana Maglio; Renli Teng; Per T Thyrum; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  Semi-synthetic glycopeptide antibacterials.

Authors:  J Kevin Judice; John L Pace
Journal:  Bioorg Med Chem Lett       Date:  2003-12-01       Impact factor: 2.823

3.  Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.

Authors:  Heather K Sun; Christine T Ong; Ambreen Umer; Dawn Harper; Steven Troy; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 4.  Treatment of skin and soft-tissue infections.

Authors:  T M File; J S Tan
Journal:  Am J Surg       Date:  1995-05       Impact factor: 2.565

5.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

6.  Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.

Authors:  Daryl Hoban; Ken Waites; David Felmingham
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  In vitro activity of TD-6424 against Staphylococcus aureus.

Authors:  John L Pace; Kevin Krause; Deborah Johnston; Dmitri Debabov; Terry Wu; Lesley Farrington; Cassie Lane; Deborah L Higgins; Burt Christensen; J Kevin Judice; Koné Kaniga
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy.

Authors:  Mark E Jones; James A Karlowsky; Deborah C Draghi; Clyde Thornsberry; Daniel F Sahm; Dilip Nathwani
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283
View more
  18 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

3.  Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Authors:  Thomas P Lodise; Mark Gotfried; Steven Barriere; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

4.  Telavancin.

Authors:  G Ralph Corey; Martin E Stryjewski; Wim Weyenberg; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

5.  Telavancin (vibativ), a new option for the treatment of gram-positive infections.

Authors:  Polina Plotkin; Khusbu Patel; Amy Uminski; Nino Marzella
Journal:  P T       Date:  2011-03

6.  A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Authors:  Sami Ullah; Peter Matzneller; Markus Zeitlinger; Uwe Fuhr; Max Taubert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-06       Impact factor: 3.000

Review 7.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

8.  Telavancin.

Authors:  Katherine A Lyseng-Williamson; Stephanie K A Blick
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

10.  Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Authors:  Mark H Gotfried; Jeng-Pyng Shaw; Bret M Benton; Kevin M Krause; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.